Alcon Inc
ALC: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$19.00 | Plwvlnf | Qmzttrlzq |
Alcon Posts Steady Q4 With Signs of Strong Surgical Demand on the Horizon
Narrow-moat Alcon posted steady fourth-quarter results, with solid top-line growth augmented by new products, and fairly robust margins in light of continued supply challenges. We see some room for a rebound through 2023-24, but this depends on procedure volumes and supply cost inflation. We don't expect any major changes to our $53 fair value estimate based on its earnings.